• Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Contact Icon Contact Icon Contact Icon
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Single Image

Doug Randall

Mr. Randall has 33 years of pharmaceutical executive experience. Prior to joining the company, Mr. Randall co-founded Phyxius Pharma, Inc. in 2011 where he served as the Chief Commercial Officer. Previously, Mr. Randall served in many senior level executive positions within the pharmaceutical industry, including: Vice President of Commercial Operations at The Medicines Company; Vice President of US Diabetes Marketing at Sanofi-Aventis Pharmaceuticals; and Vice President of Sales at Aventis Pharmaceuticals. Prior to the formation of Aventis Pharmaceuticals in 2000, Mr. Randall served in several senior commercial roles at the former legacy companies (Hoechst Marion Roussel, Marion Merrell Dow, and Marion Laboratories) including: Director of Respiratory Marketing, Director of Cardiovascular marketing, Director of GI/CNS Marketing, Director of Distribution and Pharmacy Markets, and various sales management roles. Mr. Randall started his pharmaceutical career as a sales representative for Marion Laboratories, Inc. in 1982 after earning his B.S. in Pharmacy from the University of Rhode Island

  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Contact
    • Email

Tenax Therapeutics

A Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies.

Contact Icon Contact Icon Contact Icon

© Copyright 2025 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design

  • Privacy Policy
  • Terms of Service